Benjamin F. Edwards & Company’s Myriad Genetics MYGN Stock Holding History

Benjamin F. Edwards & Company’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-100	Closed	-$3K	–	1742
2021 Q1	$3K	Hold	100	–	–	﹤0.01%	1579
2020 Q4	$2K	Hold	100	–	–	﹤0.01%	1540
2020 Q3	$1K	Hold	100	–	–	﹤0.01%	1633
2020 Q2	$1K	Hold	100	–	–	﹤0.01%	1632
2020 Q1	$1K	Hold	100	–	–	﹤0.01%	1665
2019 Q4	$3K	Sell	100 -100	-50%	-$2.75K	﹤0.01%	1723
2019 Q3	$6K	Hold	200	–	–	﹤0.01%	1536
2019 Q2	$6K	Hold	200	–	–	﹤0.01%	1567
2019 Q1	$7K	Hold	200	–	–	﹤0.01%	1413
2018 Q4	$6K	Hold	200	–	–	﹤0.01%	1413
2018 Q3	$9K	Hold	200	–	–	﹤0.01%	1298
2018 Q2	$7K	Hold	200	–	–	﹤0.01%	1352
2018 Q1	$6K	Hold	200	–	–	﹤0.01%	1377
2017 Q4	$7K	Hold	200	–	–	﹤0.01%	1289
2017 Q3	$7K	Hold	200	–	–	﹤0.01%	1255
2017 Q2	$5K	Hold	200	–	–	﹤0.01%	1240
2017 Q1	$4K	Hold	200	–	–	﹤0.01%	1201
2016 Q4	$3K	Sell	200 -100	-33%	-$1.81K	﹤0.01%	1122
2016 Q3	$6K	Buy	+300	New	+$7.61K	﹤0.01%	919
2016 Q1	–	Sell	-200	Closed	-$9K	–	1162
2015 Q4	$9K	Hold	200	–	–	﹤0.01%	865
2015 Q3	$7K	Hold	200	–	–	﹤0.01%	941
2015 Q2	$7K	Hold	200	–	–	﹤0.01%	988
2015 Q1	$7K	Hold	200	–	–	﹤0.01%	959
2014 Q4	$7K	Hold	200	–	–	﹤0.01%	855
2014 Q3	$8K	Hold	200	–	–	﹤0.01%	808
2014 Q2	$8K	Hold	200	–	–	﹤0.01%	768
2014 Q1	$7K	Hold	200	–	–	﹤0.01%	735
2013 Q4	$4K	Sell	200 -525	-72%	-$13.3K	﹤0.01%	767
2013 Q3	$17K	Sell	725 -350	-33%	-$9.94K	0.01%	530
2013 Q2	$29K	Buy	+1,075	New	+$31.2K	0.01%	427

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Benjamin F. Edwards & Company's MYGN Position: Q2 2021 in Review

Benjamin F. Edwards & Company sold out of Myriad Genetics (MYGN) in Q2 2021, closing a stake of 100 shares — an estimated $3K sold.

Benjamin F. Edwards & Company first reported a position in MYGN in Q2 2013 and held it in 30 quarters. The position peaked at $29K in Q2 2013. 201 funds tracked by Wall St. Rank hold MYGN as of Q2 2021.

Benjamin F. Edwards & Company reported no remaining Myriad Genetics position as of Q2 2021 after selling out during the quarter.
Benjamin F. Edwards & Company sold 100 Myriad Genetics shares in Q2 2021, an estimated $3K.
Benjamin F. Edwards & Company first reported a position in Myriad Genetics in Q2 2013 and held it in 30 quarters.
Benjamin F. Edwards & Company's Myriad Genetics position peaked at $29K in Q2 2013.
201 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2021.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2021, filed 11 Aug 2021.